OBJECTIVES:  To quantify the resource utilization of colorectal resections as expressed in Operating Room Time (ORT), Length of Stay (LOS) and Hospitalization Costs and to estimate the incremental burden in cancer patients. METHODS: The Premier Perspective® Database containing billing data from over 600 hospitals in the U.S was utilized. All elective inpatient LEFT (hemi-colectomy or sigmoidectomy), RIGHT (cecectomy or hemicolectomy), and lower anterior resections (LAR) from 2008-2014 were identified. Resource utilization parameters of ORT, LOS and hospital costs (2014 US Dollars) were computed from the billing data. Patient’s cancer status was identified based on ICD-9 diagnosis codes for colorectal cancer. Patient, procedure, and hospital factors were identified and included in multivariable models evaluating the association of cancer status and resource utilization. Analyses were conducted in the overall sample and within resection types and accounted for the clustering of patients within hospitals; p values of <0.05 were considered to be statistically significant. RESULTS:  A total of 111,785 patients undergoing colorectal resections were identified in the study (LEFT = 50,643; RIGHT = 47,620; LAR = 13,522) and 42.5% had colorectal cancer. The average ORT was 205 mins (SD=243), with a mean LOS of 6.2 days (SD=5.4) and overall hospital costs of $17,868 (SD=$17,655). After adjusting for patient, procedural and provider characteristics, cancer patients had significantly higher resource burden compared to patients without cancer (1.1% higher ORT,3.8% higher LOS, and 3.1% higher costs; all p values <0.05). These differences were most pronounced in patients undergoing LAR (6.7% higher ORT, 9.0% higher LOS, and 9.2% higher costs) followed by RIGHT (2.9% higher ORT, 4.4% higher LOS, and 3.6% higher costs). No significant difference based on cancer status was observed in LEFT. CONCLUSIONS: Patients undergoing colorectal resections have high economic burden and the inpatient resource utilization is higher for patients with cancer.